Review
Oncology
Lukasz Kuryk, Giulia Rodella, Monika Staniszewska, Katarzyna Wanda Pancer, Magdalena Wieczorek, Stefano Salmaso, Paolo Caliceti, Mariangela Garofalo
Summary: Malignant mesothelioma is a rare and aggressive cancer with no curative treatment for advanced disease. Recent advancements in understanding the interaction between the immune system and tumors have led to the development of immunotherapeutic approaches. This review provides an overview of new therapeutic options for mesothelioma with a focus on clinical trial results.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Jessica Menis, Giulia Pasello, Jordi Remon
Summary: Malignant pleural mesothelioma is a rare and aggressive cancer associated with asbestos exposure, with no treatment advances in the past 15 years. Immune therapeutics development may be a potential direction for the future treatment of this disease.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Review
Medicine, General & Internal
Maxime Borgeaud, Floryane Kim, Alex Friedlaender, Filippo Lococo, Alfredo Addeo, Fabrizio Minervini
Summary: Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis caused by asbestos exposure. Immune checkpoint inhibitors (ICIs) have shown superiority over standard chemotherapy in improving overall survival. However, not all patients benefit from ICIs, highlighting the need for new treatment strategies and predictive biomarkers. Combinations with chemo-immunotherapy or ICIs and anti-VEGF are being evaluated in clinical trials, while non-ICI immunotherapeutic approaches such as CAR-T cells and dendritic-cell vaccines are showing promising results in early trials.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
Matteo Perrino, Fabio De Vincenzo, Nadia Cordua, Federica Borea, Marta Aliprandi, Armando Santoro, Paolo Andrea Zucali
Summary: Malignant mesothelioma (MM) is a rare and aggressive cancer with a poor prognosis. Platinum and pemetrexed chemotherapy is currently the standard treatment for unresectable disease, but there is a lack of approved treatments for subsequent lines. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown promising results in both first line and second-third line settings for MM. However, there is a need for reliable biomarkers to improve patient selection, and various factors including histological subtype, PD-L1 expression, and tumor mutational burden have been studied with inconclusive results. Further research is needed to identify predictive biomarkers for immunotherapy in MM.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Giulio Metro, Diego Signorelli, Elio G. Pizzutilo, Laura Giannetta, Giulio Cerea, Miriam Garaffa, Alex Friedlaender, Alfredo Addeo, Martina Mandarano, Guido Bellezza, Fausto Roila
Summary: ICIs show promising therapeutic role in treating MPM, with further exploration needed on biomarkers selection for effective treatment and avoidance of immune-related side effects.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Oncology
Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Roberta Alfieri, Mara Bonelli
Summary: ICIs have emerged as a promising therapeutic option for difficult-to-treat cancers, especially showing superior efficacy in first-line treatment. Immunotherapeutic approaches for malignant pleural mesothelioma have also shown encouraging results. These novel treatments are crucial for the management of this disease.
Article
Oncology
Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Christophe Zemmour, Brice Chanez, Anne Sophie Chretien, Laurent Gorvel, Gwenaelle Gravis, Damien Bruyat, Roxane Mari, Anne Madroszyk, Thomas Cuny, Anthony Goncalves, Aaron E. Lisberg, Daniel Olive, Louis Tassy, Frederic Castinetti, Philippe Rochigneux
Summary: Data mining analysis showed that immune checkpoint inhibitor (ICI)-induced dysthyroidism (DT) was associated with improved overall survival (OS), and patients with both DT and other immune-related adverse events had even longer OS.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Anna K. Nowak, Wee Loong Chin, Synat Keam, Alistair Cook
Summary: Research has shown that immunotherapy, particularly immune checkpoint inhibitors, offers new treatment options for mesothelioma patients where previous standard treatments provided minimal benefits. Clinical trials on single agent and combination checkpoint inhibitors, as well as their combination with chemotherapy, have been conducted to explore these promising treatment avenues. Current advances in biomarker identification for predicting patients' responses to checkpoint inhibitors are also being studied to improve treatment outcomes for mesothelioma patients.
Article
Oncology
Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson
Summary: This study investigated the efficacy and safety of NIZ985 as monotherapy and in combination with spartalizumab in the treatment of advanced solid tumors. The results showed that NIZ985 demonstrated antitumor activity and was well tolerated in patients with advanced solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Ming Zheng
Summary: This study demonstrates that the neutrophil-to-lymphocyte ratio (NLR) is a valuable indicator for predicting the outcomes of immune checkpoint blockade (ICB) treatment. An NLR range of 2.0 to 3.0 is associated with optimal treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Rajiv Shah, Laura V. Klotz, Julia Glade
Summary: Pleural mesothelioma is an aggressive malignant tumor associated with asbestos exposure. Current treatment options mainly include platinum-based chemotherapy, while recent developments in combination therapy have shown improvements. Researchers are working on developing more effective, tolerable, and affordable drugs to tackle the expected increase in disease burden.
Review
Oncology
Maria Gemelli, Diego Luigi Cortinovis, Alice Baggi, Pierluigi di Mauro, Stefano Calza, Alfredo Berruti, Salvatore Grisanti, Matteo Rota
Summary: A systematic review and meta-analysis of clinical trials on the efficacy of immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) showed that combined ICI treatments have higher Progression Free Survival (PFS) and Overall Survival (OS) rates compared to single agents. However, there was a similar Overall Response Rate (ORR) and a higher rate of adverse events (AEs) with combined treatments. The efficacy of ICIs was found to be independent of the treatment line.
Article
Oncology
J. L. Leal, W. Hoang, J. Xue, B. Dunne, T. John, S. Harden
Summary: Malignant mesothelioma is a rare disease with limited treatment options. Radical trimodality approaches, including surgery, radiotherapy, and systemic chemo-and immunotherapy, have been used but are controversial. Recent changes in the standard of care include the incorporation of anti-angiogenics and immunotherapy. Histology plays a crucial role in determining the initial treatment plan.
Article
Oncology
Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pfoehler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Loeffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimmer
Summary: This study analyzed the impact of NRAS gene mutations on melanoma patients treated with immune checkpoint inhibitors. The results showed that NRAS mutations were not significantly correlated with patients' survival and treatment response, and had no correlation with the expression of the T-cell immune checkpoint molecule PD-L1.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Yefang Lao, Daoming Shen, Weili Zhang, Rui He, Min Jiang
Summary: Immune checkpoint inhibitors are an important strategy in cancer therapy, but some patients develop resistance to these inhibitors. Understanding the mechanisms of antitumor action and drug resistance is crucial to narrow down the population of resistant patients. This review discusses the antitumor action sites and mechanisms of different types of immune checkpoint inhibitors, as well as proposes current and future solutions for resistance.
Article
Oncology
David S. Hong, Olivier Rixe, Vi K. Chiu, Patrick M. Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N. Atkins, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, Anthony J. Olszanski
Summary: This study evaluated the safety and efficacy of the combination of mogamulizumab and nivolumab in patients with locally advanced or metastatic solid tumors. The results showed that the combination therapy was well tolerated but did not improve efficacy.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Patrick M. Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Stephen R. Broderick, Julie R. Brahmer, Scott J. Swanson, Keith Kerr, Changli Wang, Tudor-Eliade Ciuleanu, Gene B. Saylors, Fumihiro Tanaka, Hiroyuki Ito, Ke-Neng Chen, Moishe Liberman, Everett E. Vokes, Janis M. Taube, Cecile Dorange, Junliang Cai, Joseph Fiore, Anthony Jarkowski, David Balli, Mark Sausen, Dimple Pandya, Christophe Y. Calvet, Nicolas Girard
Summary: In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Ramaswamy Govindan, Charu Aggarwal, Scott J. Antonia, Marianne Davies, Steven M. Dubinett, Andrea Ferris, Patrick M. Forde, Edward B. Garon, Sarah B. Goldberg, Raffit Hassan, Matthew D. Hellmann, Fred R. Hirsch, Melissa L. Johnson, Shakun Malik, Daniel Morgensztern, Joel W. Neal, Jyoti D. Patel, David L. Rimm, Sarah Sagorsky, Lawrence H. Schwartz, Boris Sepesi, Roy S. Herbst
Summary: Immunotherapy has significantly impacted lung cancer care, providing durable responses and extended survival outcomes in various treatment settings. Although challenges remain in therapy selection, biomarker identification, special patient populations, and toxicity management, education and support for patients and caregivers are crucial for maximizing the benefits of immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O'Dwyer, A. P. Chen, K. T. Flaherty
Summary: The NCI-MATCH study aims to evaluate the efficacy of targeted therapies in histology-agnostic malignancies with driver mutations. It was found that patients with rare tumors harboring ALK or ROS1 rearrangements may respond to crizotinib treatment.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Matthew Z. Guo, Joseph C. Murray, Paola Ghanem, K. Ranh Voong, Russell K. Hales, David Ettinger, Vincent K. Lam, Christine L. Hann, Patrick M. Forde, Julie R. Brahmer, Benjamin P. Levy, Josephine L. Feliciano, Kristen A. Marrone
Summary: This study retrospectively analyzed the effectiveness of durvalumab immunotherapy consolidation for patients with KRAS-mutated stage III NSCLC. The results showed that patients with KRAS-mutated disease can derive similar benefits from durvalumab as patients with non-KRAS-mutated disease. Furthermore, a higher rate of extrathoracic progression was observed among patients with KRAS-mutated NSCLC.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Melinda L. Hsu, Joseph C. Murray, Kevin J. Psoter, Jiajia Zhang, Durrant Barasa, Julie R. Brahmer, David S. Ettinger, Patrick M. Forde, Christine L. Hann, Vincent K. Lam, Benjamin Levy, Kristen A. Marrone, Tricia Patel, Valerie Peterson, Sarah Sagorsky, Michelle Turner, Valsamo Anagnostou, Jarushka Naidoo, Josephine L. Feliciano
Summary: This study identifies a significant proportion of survivors of non-small cell lung cancer (NSCLC) treated with anti-PD-(L)1 immune checkpoint inhibitors (ICI) who experience unresolved long-term toxicities. These findings highlight the need to better understand long-term toxicities in order to optimize the management of patients treated with ICIs.
Article
Oncology
Biagio Ricciuti, Xinan Wang, Joao Alessi, Hira Rizvi, Navin R. Mahadevan, Yvonne Y. Li, Andrew Polio, James Lindsay, Renato Umeton, Rileen Sinha, Natalie Vokes, Gonzalo Recondo, Giuseppe Lamberti, Marissa Lawrence, Victor R. Vaz, Giulia C. Leonardi, Andrew J. Plodkowski, Hersh Gupta, Andrew D. Cherniack, Michael Y. Tolstorukov, Bijaya Sharma, Kristen D. Felt, Justin F. Gainor, Arvind Ravi, Gad Getz, Kurt A. Schalper, Brian Henick, Patrick Forde, Valsamo Anagnostou, Pasi A. Janne, Eliezer M. Van Allen, Mizuki Nishino, Lynette M. Sholl, David C. Christiani, Xihong Lin, Scott J. Rodig, Matthew D. Hellmann, Mark M. Awad
Summary: This study reveals the association between different tumor mutation burden (TMB) levels and immunotherapy efficacy in non-small cell lung cancer (NSCLC) patients. The findings show that increasing TMB levels are associated with immune cell infiltration and an inflammatory T-cell-mediated response.
Review
Oncology
David E. Gerber, Harpreet Singh, Erin Larkins, Andrea Ferris, Patrick M. Forde, Wendy Selig, Upal Basu Roy
Summary: Clinical trial eligibility criteria play a crucial role in controlling patient characteristics, ensuring participant safety, and optimizing result interpretation. However, complex and overly restrictive criteria have posed barriers to patient access, recruitment, and the generalizability of trial results. In response, a working group developed a framework for lung cancer clinical trial eligibility criteria, aiming to simplify criteria, facilitate stakeholder search for trials, and harmonize trial populations for treatment effect comparisons.
Article
Oncology
Michael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, Guangfan Zhang, James R. White, Zineb Belcaid, Christopher Cherry, Archana Balan, Gavin Pereira, Alexandria Curry, Noushin Niknafs, Jiajia Zhang, Kellie N. Smith, Lavanya Sivapalan, Jamie E. Chaft, Joshua E. Reuss, Kristen Marrone, Joseph C. Murray, Qing Kay Li, Vincent Lam, Benjamin P. Levy, Christine Hann, Victor E. Velculescu, Julie R. Brahmer, Patrick M. Forde, Tanguy Seiwert, Valsamo Anagnostou
Summary: Through machine learning, this study integrated the dynamics of peripheral blood immune cell subsets and predicted clinical outcomes for 239 patients with metastatic non-small cell lung cancer. The findings suggest that the integrated dynamics of peripheral blood cell counts, particularly changes in NLR, can predict therapeutic response better than traditional biomarkers like TMB and PD-L1 expression. Early changes in NLR were identified as a key predictor of treatment response.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Editorial Material
Biochemistry & Molecular Biology
Michael Conroy, Patrick M. Forde
Summary: The NEOSTAR trial is an important step towards improving outcomes, but a personalized approach taking into account various factors influencing treatment response is likely the best approach.
Article
Biochemistry & Molecular Biology
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, Patrick M. Forde, Jonathan Spicer, Nicolas Girard, Daphne Wang, Robert A. Anders, Edward Gabrielson, Peter Illei, Jaroslaw Jedrych, Ludmila Danilova, Joel Sunshine, Keith M. Kerr, Mia Tran, Judith Bushong, Junliang Cai, Vipul Devas, Jaclyn Neely, David Balli, Tricia R. Cottrell, Alex S. Baras, Janis M. Taube
Summary: Neoadjuvant immunotherapy plus chemotherapy improves event-free survival and pathologic response in resectable lung cancer. Pathologic response assessment after neoadjuvant therapy may serve as a survival surrogate.
Review
Oncology
Giannis Mountzios, Jordi Remon, Lizza E. L. Hendriks, Rosario Garcia-Campelo, Christian Rolfo, Paul Van Schil, Patrick M. Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean-Charles Soria, Solange Peters
Summary: Several trials are being conducted to test immune-checkpoint inhibitors (ICIs) in patients with resectable non-small-cell lung cancer as adjuvant, neoadjuvant or perioperative approaches. However, the efficacy of ICIs with curative intent in early stage non-small-cell lung cancer remains unclear. This review discusses the current trial landscape, challenges, and opportunities.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Letter
Medicine, General & Internal
Patrick M. Forde, Jonathan Spicer, Nicolas Girard
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Kai-li Liang, Sean Tackett, Samantha Myers, Julie R. Brahmer, Ilene S. Browner, David S. Ettinger, Patrick M. Forde, Russell K. Hales, Christine L. Hann, Vincent K. Lam, Kristen A. Marrone, Tricia Patel, Valerie Peterson, Sarah Sagorsky, Michelle Turner, Khinh R. Voong, Jarushka Naidoo, Josephine L. Feliciano
Summary: This study found that the majority of immune-related adverse events (irAEs) seen in an urgent care setting were safely managed within the center. Patients treated with immune checkpoint inhibitors (ICI) had an increased risk of hospitalization if they experienced an irAE.
Article
Clinical Neurology
Pavan P. Shah, Jennifer L. Franke, Ravi Medikonda, Christopher M. Jackson, Siddhartha Srivastava, John Choi, Patrick M. Forde, Julie R. Brahmer, David S. Ettinger, Josephine L. Feliciano, Benjamin P. Levy, Kristen A. Marrone, Jarushka Naidoo, Kristin J. Redmond, Lawrence R. Kleinberg, Michael Lim
Summary: This study retrospectively analyzed NSCLC brain metastasis cases with available molecular testing data. The results showed that EGFR mutated patients who received TKI therapy had significantly prolonged survival after surgery.
JOURNAL OF NEUROSURGERY
(2022)